127 related articles for article (PubMed ID: 20534902)
21. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas.
Nicotra G; Mercalli F; Peracchio C; Castino R; Follo C; Valente G; Isidoro C
Mod Pathol; 2010 Jul; 23(7):937-50. PubMed ID: 20473282
[TBL] [Abstract][Full Text] [Related]
22. CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
Carulli G; Cannizzo E; Zucca A; Buda G; Orciuolo E; Marini A; Petrini M
Leuk Res; 2008 Feb; 32(2):263-7. PubMed ID: 17692374
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
Kingma DW; Medeiros LJ; Barletta J; Raffeld M; Mann RB; Ambinder RF; Jaffe ES
Am J Surg Pathol; 1994 Jan; 18(1):48-61. PubMed ID: 8279628
[TBL] [Abstract][Full Text] [Related]
24. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
Xiao C; Su ZL; Wu QL; Gao HY; Fang JC; Xia ZJ; Guan ZZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):22-7. PubMed ID: 15796877
[TBL] [Abstract][Full Text] [Related]
26. ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas.
Zhu X; Miao X; Wu Y; Li C; Guo Y; Liu Y; Chen Y; Lu X; Wang Y; He S
Exp Cell Res; 2015 Jul; 335(2):216-23. PubMed ID: 26024773
[TBL] [Abstract][Full Text] [Related]
27. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
28. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
Visco C; Medeiros LJ; Jones D; Smith T; Rodriguez MA; McLaughlin P; Romaguera J; Cabanillas F; Sarris AH
Ann Oncol; 2002 Aug; 13(8):1290-9. PubMed ID: 12181254
[TBL] [Abstract][Full Text] [Related]
29. Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.
Sung CO; Ko YH; Park S; Kim K; Kim W
J Korean Med Sci; 2005 Dec; 20(6):952-6. PubMed ID: 16361803
[TBL] [Abstract][Full Text] [Related]
30. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy.
Valente G; Manfroi F; Peracchio C; Nicotra G; Castino R; Nicosia G; Kerim S; Isidoro C
Br J Haematol; 2006 Mar; 132(5):560-70. PubMed ID: 16445828
[TBL] [Abstract][Full Text] [Related]
31. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
32. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
34. Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification.
Hatta C; Ogasawara H; Okita J; Kubota A; Ishida M; Sakagami M
Auris Nasus Larynx; 2001 Jan; 28(1):55-60. PubMed ID: 11137364
[TBL] [Abstract][Full Text] [Related]
35. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.
Pinyol M; Cobo F; Bea S; Jares P; Nayach I; Fernandez PL; Montserrat E; Cardesa A; Campo E
Blood; 1998 Apr; 91(8):2977-84. PubMed ID: 9531609
[TBL] [Abstract][Full Text] [Related]
36. CD30 expression in non-Hodgkin's lymphoma.
Piris M; Brown DC; Gatter KC; Mason DY
Histopathology; 1990 Sep; 17(3):211-8. PubMed ID: 2173674
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidylaminopeptidase IV activity in T lymphocyte subsets in B cell non-Hodgkin's lymphomas.
Cozzi M; Gloghini A; Sulfaro S; Volpe R; Carbone A
Hum Pathol; 1989 Oct; 20(10):987-93. PubMed ID: 2571558
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
[TBL] [Abstract][Full Text] [Related]
39. [Non-Hodgkin's lymphomas. I. Clinico-biological features of 307 cases].
García Zueco JC; Delgado MP; Giraldo MP; Perella M; Torres M; Valero MI; Ríos MJ; García Julián G; Giralt M
Sangre (Barc); 1992 Oct; 37(5):331-6. PubMed ID: 1293771
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO.
d'Amore F; Johansen P; Houmand A; Weisenburger DD; Mortensen LS
Blood; 1996 Feb; 87(3):1045-55. PubMed ID: 8562929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
